Clinical Trial Update: β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of beta-elemene with an EGFR-TKI in advanced EGFR-TKI–resistant non-small cell lung cancer (status: unknown).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGFR-TKI (EGFR tyrosine kinase inhibitor)
• beta-elemene (beta-elemene)

Snippet

Sponsor: China Medical University, China | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN